Literature DB >> 29972652

Depression symptoms and quality of life among individuals with aspirin-exacerbated respiratory disease.

Jonathan M Feldman1,2, Ariel E Zeigler1, Krista Nelson1, Esperanza Morales-Raveendran1, Teresa Pelletier3, Gigia Roizen2, Zhen Ren4, Elina Jerschow2.   

Abstract

OBJECTIVE: Patients with aspirin-exacerbated respiratory disease (AERD) have high disease burden due to the severity of asthma and sinonasal symptoms. There is limited research on the psychological well-being and subjective experiences of patients with AERD. This study examined levels of depression symptoms, asthma-related quality of life and asthma control among AERD patients.
METHODS: Thirty-two adults with AERD and 39 patients without AERD (asthma-only) were recruited from outpatient asthma/allergy clinics. The sample was largely comprised of ethnic minority, inner-city patients who ranged in age from 19 to 84 years old. Participants completed the Beck Depression Inventory (BDI), the Mini Asthma Quality of Life Questionnaire (Mini AQLQ), a self-report rating of asthma severity and spirometry testing. Asthma control and severity were determined following national guidelines.
RESULTS: AERD patients reported lower levels of depression symptoms (p = 0.049), better overall asthma-related quality of life (p < 0.001), and perceived their asthma to be less severe (p = 0.01) compared to asthma-only patients. However, clinician ratings of asthma severity were more severe for AERD than asthma-only patients (p = 0.006). No significant differences were found between the groups on asthma controller medications or oral corticosteroid bursts for asthma.
CONCLUSIONS: AERD patients may be resilient given their low levels of depression symptoms and positive views of asthma-related impairment despite higher clinician-rated asthma severity. The adult onset nature of asthma in AERD might be a protective factor on mental health. Future studies should explore mechanisms linking AERD and positive psychological health outcomes and subjective perception of asthma.

Entities:  

Keywords:  Mental health; minority groups; protective factors; resilience; signs and symptoms

Mesh:

Year:  2018        PMID: 29972652      PMCID: PMC6467719          DOI: 10.1080/02770903.2018.1490754

Source DB:  PubMed          Journal:  J Asthma        ISSN: 0277-0903            Impact factor:   2.515


  42 in total

1.  Development and validation of a questionnaire to measure asthma control.

Authors:  E F Juniper; P M O'Byrne; G H Guyatt; P J Ferrie; D R King
Journal:  Eur Respir J       Date:  1999-10       Impact factor: 16.671

2.  Natural history of aspirin-induced asthma. AIANE Investigators. European Network on Aspirin-Induced Asthma.

Authors:  A Szczeklik; E Nizankowska; M Duplaga
Journal:  Eur Respir J       Date:  2000-09       Impact factor: 16.671

3.  Psychiatric diagnoses in inner city outpatients with moderate to severe asthma.

Authors:  E S Brown; D A Khan; S Mahadi
Journal:  Int J Psychiatry Med       Date:  2000       Impact factor: 1.210

4.  Adaptation of the Asthma Quality of Life Questionnaire to a second language preserves its critical properties: the Spanish version.

Authors:  C Sanjuás; J Alonso; M Ferrer; V Curull; J M Broquetas; J M Antó
Journal:  J Clin Epidemiol       Date:  2001-02       Impact factor: 6.437

5.  The natural history and clinical characteristics of aspirin-exacerbated respiratory disease.

Authors:  M Pilar Berges-Gimeno; Ronald A Simon; Donald D Stevenson
Journal:  Ann Allergy Asthma Immunol       Date:  2002-11       Impact factor: 6.347

6.  Early effects of aspirin desensitization treatment in asthmatic patients with aspirin-exacerbated respiratory disease.

Authors:  M Pilar Berges-Gimeno; Ronald A Simon; Donald D Stevenson
Journal:  Ann Allergy Asthma Immunol       Date:  2003-03       Impact factor: 6.347

7.  Psychiatric disorders and asthma outcomes among high-risk inner-city patients.

Authors:  Jonathan M Feldman; Mahmood I Siddique; Enid Morales; Beverly Kaminski; Shou-En Lu; Paul M Lehrer
Journal:  Psychosom Med       Date:  2005 Nov-Dec       Impact factor: 4.312

8.  Behavioral adjustment in children with asthma: a meta-analysis.

Authors:  E L McQuaid; S J Kopel; J H Nassau
Journal:  J Dev Behav Pediatr       Date:  2001-12       Impact factor: 2.225

9.  Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease.

Authors:  M Pilar Berges-Gimeno; Ronald A Simon; Donald D Stevenson
Journal:  J Allergy Clin Immunol       Date:  2003-01       Impact factor: 10.793

10.  Mental disorders and asthma in the community.

Authors:  Renee D Goodwin; Frank Jacobi; Wolfgang Thefeld
Journal:  Arch Gen Psychiatry       Date:  2003-11
View more
  4 in total

Review 1.  The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: A Work Group Report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy, Asthma & Immunology.

Authors:  Whitney W Stevens; Elina Jerschow; Alan P Baptist; Larry Borish; John V Bosso; Kathleen M Buchheit; Katherine N Cahill; Paloma Campo; Seong H Cho; Anjeni Keswani; Joshua M Levy; Anil Nanda; Tanya M Laidlaw; Andrew A White
Journal:  J Allergy Clin Immunol       Date:  2020-12-09       Impact factor: 10.793

2.  Effect of asthma control on general health-related quality of life in patients diagnosed with adult-onset asthma.

Authors:  Pinja Ilmarinen; Hind Juboori; Leena E Tuomisto; Onni Niemelä; Harri Sintonen; Hannu Kankaanranta
Journal:  Sci Rep       Date:  2019-11-06       Impact factor: 4.379

3.  The impact of endoscopic sinus surgery and aspirin desensitization on psychological burden in aspirin-exacerbated respiratory disease.

Authors:  Tran Locke; Auddie Sweis; Theodore Lin; Brian Sweis; Patrick Gleeson; Michael Kohanski; Nithin Adappa; James Palmer; John Bosso
Journal:  World J Otorhinolaryngol Head Neck Surg       Date:  2020-10-22

4.  Patient-Reported Control of Asthma, Nasal Polyposis, and Middle-Ear Symptoms in NSAID-Exacerbated Respiratory Disease.

Authors:  Anna Suikkila; Lena Hafrén; Annina Lyly; Tuomas Klockars; Riitta Saarinen
Journal:  Front Allergy       Date:  2021-07-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.